Clinical trials
Observational Pre-Eclampsia trials in the United Kingdom
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
17 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2011 | 1 |
| 2013 | 2 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 2 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 9 |
| Completed | 3 |
| Recruiting | 2 |
| Terminated | 2 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| University of Oxford | 4 |
| Oxford University Hospitals NHS Trust | 2 |
| Queen Mary University of London | 2 |
| Assaf-Harofeh Medical Center | 1 |
| Croydon University Hospital | 1 |
| Imperial College Healthcare NHS Trust | 1 |
| Louise Kenny | 1 |
| Manchester Academic Health Science Centre | 1 |
| Ottawa Hospital Research Institute | 1 |
| Recep Tayyip Erdogan University Training and Research Hospital | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Pre-Eclampsia | 17 |
| Fetal Growth Retardation | 5 |
| Hypertension, Pregnancy-Induced | 5 |
| Cardiovascular Diseases | 3 |
| Diabetes, Gestational | 3 |
| Hypertension | 3 |
| Pregnancy Complications | 3 |
| Premature Birth | 2 |
| Stillbirth | 2 |
| Abortion, Spontaneous | 1 |
Trials
Showing 1 to 17 of 17. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.